Tuesday, October 28, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

KB Home Shares Face Mounting Pressure as Short Interest Climbs

Robert Sasse by Robert Sasse
September 10, 2025
in Analysis, Real Estate & REITs, Trading & Momentum
0
KB Home Stock
0
SHARES
106
VIEWS
Share on FacebookShare on Twitter

KB Home’s stock is underperforming the broader homebuilder sector, declining 2.80% to $65.92. While industry peers are posting strong gains, the company contends with a significant rise in bearish bets and conflicting analyst assessments.

Fundamental Performance Shows Strain

Recent quarterly results reveal clear operational challenges. Revenue fell 10.5% to $1.53 billion, while earnings per share dropped sharply from $2.15 to $1.50. Current projections anticipate a 23.3% decline in profit for this year, though analysts forecast a potential recovery with an 8.55% increase next year. Despite these headwinds, valuation metrics appear attractive with a price-to-earnings ratio of 8.95.

Short Sellers Target Homebuilder

A notable development for KB Home is the substantial increase in short interest. Currently, 6.16 million shares have been sold short, representing 9.43% of the free float. This marks a 12.20% surge within just one month, indicating growing skepticism among investors. The Days to Cover ratio stands at 4.0, suggesting increased vulnerability to positive news catalysts that could trigger a short squeeze.

Should investors sell immediately? Or is it worth buying KB Home?

Divergence From Sector Strength

The company’s weakness contrasts sharply with sector performance. Over the past four weeks, the homebuilding industry has advanced 15.7%, significantly outpacing KB Home’s performance. This discrepancy suggests investors are focusing on company-specific concerns rather than broader industry optimism.

Mixed Analyst Sentiment Persists

Market experts remain divided on KB Home’s prospects:

  • Oppenheimer initiated coverage with a “Perform” rating, acknowledging opportunities in the build-to-order model while noting concerns about market positioning
  • Raymond James maintained its “Outperform” recommendation, highlighting what it views as an attractive risk/reward profile
  • Keefe, Bruyette & Woods reduced its price target to $58, citing margin compression and lowered delivery forecasts

The critical question remains whether KB Home can deliver on next year’s expected recovery or face additional pressure from short sellers if performance continues to disappoint.

Ad

KB Home Stock: Buy or Sell?! New KB Home Analysis from October 28 delivers the answer:

The latest KB Home figures speak for themselves: Urgent action needed for KB Home investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 28.

KB Home: Buy or sell? Read more here...

Tags: KB Home
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Sarepta Therapeutics Stock
Analysis

Sarepta Therapeutics Faces Critical Earnings Test Amid Regulatory Uncertainty

October 28, 2025
aTyr Pharma Stock
Analysis

Biotech Firm aTyr Pharma Faces Investor Lawsuits Following Clinical Trial Setback

October 28, 2025
Amgen Stock
Analysis

Amgen’s Pivotal Moment: Legal Win Sets Stage for Critical Earnings Report

October 28, 2025
Next Post
Robinhood Stock

Robinhood's Strategic Expansion: From Broker to Financial Powerhouse

American Eagle Outfitters Stock

Marketing Prowess Fuels American Eagle Outfitters' Stellar Quarter

Rocket Lab USA Stock

Rocket Lab Navigates Legal Challenges While Pushing Ambitious Space Agenda

Recommended

Cricut Stock

Cricut’s Aggressive Discount Strategy Aims to Revive Slumping Sales

3 weeks ago
Red Cat Stock

Red Cat Stock Plummets Despite Major Defense Sector Expansion

2 months ago
Childrens Place Stock

Children’s Place Faces Pivotal Earnings Test Amid Strategic Overhaul

2 months ago
Robinhood Stock

Robinhood’s Strategic Expansion into Prediction Markets

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Biotech Firm aTyr Pharma Faces Investor Lawsuits Following Clinical Trial Setback

Amgen’s Pivotal Moment: Legal Win Sets Stage for Critical Earnings Report

Centrus Energy Shares Signal Potential Market Reversal

Acquisition Battle Intensifies for Warner Bros. Discovery

First Solar Shares Continue Their Record-Breaking Ascent

Tech Stocks Soar as Nasdaq 100 Reaches Unprecedented Peak

Trending

Texas Instruments Stock
Earnings

Texas Instruments Shares Tumble Following Disappointing Earnings Outlook

by Andreas Sommer
October 28, 2025
0

Texas Instruments, a major player in the semiconductor industry, is facing significant headwinds. The company's stock experienced...

Philip Morris Stock

Investor Skepticism Meets Strong Performance at Philip Morris

October 28, 2025
Sarepta Therapeutics Stock

Sarepta Therapeutics Faces Critical Earnings Test Amid Regulatory Uncertainty

October 28, 2025
aTyr Pharma Stock

Biotech Firm aTyr Pharma Faces Investor Lawsuits Following Clinical Trial Setback

October 28, 2025
Amgen Stock

Amgen’s Pivotal Moment: Legal Win Sets Stage for Critical Earnings Report

October 28, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Texas Instruments Shares Tumble Following Disappointing Earnings Outlook
  • Investor Skepticism Meets Strong Performance at Philip Morris
  • Sarepta Therapeutics Faces Critical Earnings Test Amid Regulatory Uncertainty

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com